-+ 0.00%
-+ 0.00%
-+ 0.00%

B of A Securities Initiates Coverage On Immix Biopharma with Buy Rating, Announces Price Target of $27

Benzinga·06/18/2026 10:17:06
Listen to the news
B of A Securities analyst Tazeen Ahmad initiates coverage on Immix Biopharma (NASDAQ:IMMX) with a Buy rating and announces Price Target of $27.